Click here to listen to previous episodes.
About Chen Lin
Author "What is Chen Buying? What is Chen Selling?" Chen grew $5,400 to $2.3 million in 10 years. Learn More
BlackRock: Opportunities Abound In Biotech, Healthcare
From BlackRock: A dynamic of haves versus have-nots means that health care is increasingly all about stock picking. Kate Moore sees opportunities in biotech, medical devices, U.S. managed care and selected big pharma with promising drug pipelines.
Health care stocks are playing catch-up after about six quarters of underperformance, with many stocks still in the bargain bin, particularly beaten-up biotechs.
Is health care a buy? We think a selective approach is appropriate. Health care has a lower stock correlation than other sectors, reflecting variations in innovation cycles, drug patents and pipelines. That dynamic reinforces the importance of selecting winners and avoiding losers.
Health care stocks have historically traded at a premium to the broader equity market, partly reflecting their growth characteristics and popularity as a source of income. Yet today some sub-industries such as biotech sell at a discount. Many trade near the bottom of their historical valuation range, as the Bargain bin chart shows.
The health care sector is made up of haves (those with potential category-killer medical products including drugs, devices and diagnostics) and have-nots (companies in areas that face generic competition or product obsolescence). An appropriate strategy is focusing on the merits of individual stocks rather than the attributes of the entire sector.
A challenge for drug makers is that politicians, regulators and consumers are clamoring to curb growth in drug prices. U.S. prescription drug prices rose 5.2% in 2016, the largest increase since 2001, according to the Bureau of Economic Analysis. An ongoing Republican attempt to “repeal and replace” Obamacare may lead to more political uncertainties for some health insurers and hospitals. Yet worries about drug pricing and other policy risks are largely reflected in valuations.
With most large-cap pharma companies in the mature stage of product development, many are seeking to buy growth. U.S. tax reforms encouraging repatriation of overseas cash could trigger a surge in mergers and acquisitions. Pharmaceutical companies will dominate M&A in 2017 if history is a guide.
We see opportunities in biotech, medical device makers, U.S. managed care companies and selected big pharma with promising drug pipelines. Investors can wait for a catalyst such as a takeover (selected small and mid caps) or pocket steady dividends until the market reprices the value of a pipeline. When investing in health care, it’s important to be selective. Read more on this in my latest Global Equity Outlook publication.
The iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) was unchanged in premarket trading Monday. Year-to-date, IBB has gained 10.51%, versus a 5.46% rise in the benchmark S&P 500 index during the same period.
IBB currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #2 of 36 ETFs in the Health & Biotech ETFs category.
Kate Moore is BlackRock’s Chief Equity Strategist and a regular contributor to The Blog.
This article is brought to you courtesy of BlackRock.
You are viewing an abbreviated republication of ETF Daily News content. You can find full ETF Daily News articles on (www.etfdailynews.com)
Powered by WPeMatico